Likewise, the combination of ferroptosis agonists (erastin and RSL3) and STAT3 (signal transducer and activator of transcription 3) inhibitors synergistically impaired the cisplatin resistance in osteosarcoma MG63 and Saos-2 cells (Liu and Wang, 2019). The gene discussed is STAT3; the disease is osteosarcoma.